Spero Therapeutics Inc R&D Event Transcript
Good morning, and welcome to the Spero Therapeutics R&D Day. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the Spero website following the conclusion of the event. I'd now like to turn the call over to Ted Jenkins, Vice President and Head of Investor Relations at Spero Therapeutics. Please go ahead, Ted.
Thank you, Tara, and thank you all for participating in today's discussion on non-tuberculous mycobacterial or NTM pulmonary disease along with the Spero presentation of SPR720, our novel first-line candidate, broad spectrum oral antibacterial agent in development to treat NTM infections. Before we begin, I'd like to remind you that some of the information presented on this conference call contains certain forward-looking statements based on our current expectations, including statements with the future development and commercialization of SPR720, SPR206 and tebipenem HBr, and the design, initiation, timing, progress and results of the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
